Skip to content

Treatment for Reducing Respiratory Distress in COVID-19 Patients

A simple LMWHA diagnostic could be used as a companion diagnostic to identify responders to N-butyryl HA therapy

Published: 10th June 2021
Treatment for Reducing Respiratory Distress in COVID-19 Patients
Piotr Adamczyk, stock.adobe.com
Patents
  • US 9,644,050 “Hyaluronic Acid Derivatives”
  • Japanese Patent JP6363119B2
  • Canadian Patent 2,905,610 "Hyaluronic Acid Derivatives"
  • Patents pending on use in gout, hyperuricemia and wound healing in US, Canada and China
IP Status
  • Patented
  • Provisional patent
Seeking
  • Development partner
  • Seeking investment